Sung Simon, Margolskee Elizabeth, Chen Diane, Tiscornia-Wasserman Patricia
Department of Pathology and Cell Biology, Columbia University Medical Center/New York Presbyterian, New York, New York.
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York.
J Am Soc Cytopathol. 2019 May-Jun;8(3):133-140. doi: 10.1016/j.jasc.2019.01.005. Epub 2019 Jan 22.
The second edition of The Bethesda System for Reporting Thyroid Cytopathology has incorporated the recent change in nomenclature, noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), with an anticipated change in the risk of malignancy (ROM). We examined our institutional experience in the incidence of NIFTP and the change in the ROM in The Bethesda System for Reporting Thyroid Cytopathology.
A computerized search was performed from January 2013 to August 2017 for all thyroid fine needle aspirations (FNAs), the corresponding surgical resection specimens, and clinical follow-up data. All thyroid specimens reported as follicular variant of papillary thyroid carcinoma were reviewed and reclassified, and all NIFTP diagnoses from April 2016 to August 2017 were identified. The ROM for each category was calculated before and after the change and analyzed for significance.
A total of 4500 thyroid FNA cases were collected. Of these, 479 cases had surgical resection specimens available and 36 cases had been diagnosed as NIFTP. Of these, 22 had been previously diagnosed as FVPT. Of 27 cases of NIFTP, 14 and 13 were atypia of undetermined significance/follicular lesion of undetermined significance and follicular neoplasm/suspicious for follicular neoplasm, respectively. A reduction in the ROM was observed in these 2 categories (P = 0.03 and P = 0.04, respectively).
In our institution, NIFTP has accounted for 13% of all malignant thyroid neoplasms since the change in nomenclature. Although the ROM was decreased in the affected categories, with absolute statistically significant decreases in ROM of 15% and 16.2% for category III and IV, respectively, the overall ROM change was marginal.
《甲状腺细胞病理学报告的贝塞斯达系统》第二版纳入了最近的术语变化,即具有乳头样核特征的非侵袭性滤泡性甲状腺肿瘤(NIFTP),预计其恶性风险(ROM)会发生变化。我们研究了我们机构在NIFTP发病率以及《甲状腺细胞病理学报告的贝塞斯达系统》中ROM变化方面的经验。
对2013年1月至2017年8月期间所有甲状腺细针穿刺活检(FNA)、相应的手术切除标本以及临床随访数据进行计算机检索。对所有报告为甲状腺乳头状癌滤泡变体的甲状腺标本进行复查和重新分类,并确定2016年4月至2017年8月期间所有NIFTP诊断病例。计算变化前后各分类的ROM,并分析其显著性。
共收集到4500例甲状腺FNA病例。其中,479例有手术切除标本,36例被诊断为NIFTP。其中,22例之前被诊断为FVPT。在27例NIFTP病例中,14例和13例分别为意义不明确的非典型性/意义不明确的滤泡性病变以及滤泡性肿瘤/可疑滤泡性肿瘤。这两类的ROM均有所降低(分别为P = 0.03和P = 0.04)。
在我们机构,自术语变化以来,NIFTP占所有恶性甲状腺肿瘤的13%。尽管受影响分类的ROM有所降低,III类和IV类的ROM绝对统计学显著降低分别为15%和16.2%,但总体ROM变化很小。